Trial Profile
An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer With Repeated Administration Courses in Patients With Clinical Benefit
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2014
Price :
$35
*
At a glance
- Drugs Bivatuzumab mertansine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 08 Oct 2014 New trial record